Novo Nordisk partners with US biotech company on diabetes

Novo Nordisk will fund further preclinical development of potential drug candidates.
Photo: Finn Frandsen
Photo: Finn Frandsen
by MARKETWIRE

Novo Nordisk has entered into a collaboration with US-based Biosplice Therapeutics to develop small molecule drugs for the treatment of diabetes, an announcement from the American company states.

Under the agreement, Novo Nordisk will fund further preclinical development of potential drug candidates and Novo Nordisk will also have an exclusive option to in-license Biosplice’s rights in cardiometabolic diseases such as obesity, diabetes and cardiovascular disease.

Financial details of the agreement have not been disclosed, but it involves an upfront payment, milestone payments and royalties, according to Biosplice, based in San Diego, California.

English edit: Catherine Brett

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Mike Blake/Reuters/Ritzau Scanpix

Gilead Sciences CMO to leave early 2025

For subscribers

Further reading